Back to User profile » Dr Thomas LeBlanc
Papers published by Dr Thomas LeBlanc:
An Updated Indirect Comparison of Elranatamab Versus a Real-World External Control Arm in Triple-Class Refractory Multiple Myeloma
Costa LJ, LeBlanc TW, Tesch H, Sonneveld P, Johnson SM, Vekeman F, Hlavacek P, Meche A, Kim CH, Cislo P, Hughes DM, Nador G, DiBonaventura M
Blood and Lymphatic Cancer: Targets and Therapy 2025, 15:11-20
Published Date: 5 June 2025
Matching-Adjusted Indirect Comparison of Elranatamab versus Teclistamab in Patients with Triple-Class Exposed/Refractory Multiple Myeloma: Updated Results
Mol I, Hu Y, LeBlanc TW, Cappelleri JC, Chu H, Nador G, Aydin D, Perez Cruz I, Hlavacek P
Journal of Blood Medicine 2025, 16:233-239
Published Date: 14 May 2025
Multiple Myeloma Experiences and Preferences: A Mixed Methods Study of Patients and Care Partners in the United States
Flora DR, Byrd R, Platt DA, Hlavacek P, Hoag Goldman E, Cappelleri JC, Kennedy CT, LeBlanc TW
Patient Preference and Adherence 2025, 19:963-979
Published Date: 8 April 2025
Patient, Care Partner, and Physician Voices in Treatment Decision-Making for Multiple Myeloma
Dwyer Orr L, Lin D, Wu B, LeBlanc TW, Faiman B, Ahlstrom J, Yung M, Deering KL, Kulbokas V, Feldman JL, Kline E, Biran N
Patient Preference and Adherence 2024, 18:2147-2158
Published Date: 19 October 2024
Oncologist and Patient Preferences for Novel Agents in First-Line Treatment for Chronic Lymphocytic Leukemia: Commonalities and Disconnects
Le H, Ryan K, Wahlstrom SK, Maculaitis MC, Will O, Mulvihill E, LeBlanc TW
Patient Preference and Adherence 2021, 15:99-110
Published Date: 22 January 2021